The StatinTB Consortium has published a systematic review and meta-analysis evaluating the impact of statins on inflammatory markers and lipid profiles in adults with chronic diseases (https://doi.org/10.1371/journal.pone.0323749).

Statins are medications widely known for lowering cholesterol. But they also have other benefits, especially in reducing inflammation. While many studies have shown these broader effects, few have looked specifically at how well statins reduce inflammation in people with chronic illnesses.

In this study, Solima Sabeel, Bongani Motaung, and Reto Guler from the University of Cape Town, Kim Nguyen from the South African Medical Research Council, and other StatinTB consortium members, reviewed and analyzed data from randomised controlled trials from over two decades of clinical trials to see how statins affect inflammation and cholesterol levels in patients with chronic illnesses like cardiovascular disease and chronic renal failure. It was found that statins significantly reduce key markers of inflammation (IL-6, TNF-α, and CRP). Among all statins, atorvastatin had the strongest impact on reducing IL-6 and TNF-α, especially when taken for more than four months.

These findings highlight the anti-inflammatory potential of statins beyond cholesterol regulation, especially with long-term use.

This publication directly supports the scientific rationale behind the StatinTB clinical trial, which investigates whether atorvastatin can be repurposed to reduce persistent lung inflammation following tuberculosis treatment.

The study provides evidence that can guide future clinical trials and inform evidence-based treatment protocols. It suggests that clinicians can consider the differential efficacy of different statins in modulating inflammation when tailoring treatment strategies for patients – and help manage chronic diseases by not only lowering cholesterol levels but also inflammation through the use of statins.